Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Cancer immunology, immunotherapy : CII
Biomarkers; CTLA-4; Immunotherapy; OX-40; PD-1; PD-L1
A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.
Earle A. Chiles Research Institute
Maio, Michele; Coukos, George; Ferrone, Soldano; Fox, Bernard A; Fridman, Wolf H; Garcia, Patrick L; Lahn, Michael; Provendier, Olivier; Russo, Vincenzo; Rüttinger, Dominik; Shalabi, Aiman; Trajanoski, Zlatko; Viallet, Jean; Wolchok, Jedd D; and Ibrahim, Ramy, "Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy." (2019). Articles, Abstracts, and Reports. 889.